Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), a well-known bio-pharmaceutical company released its 1Q2014 report on May 8, 2014. The company that has completely focused on the development as well as commercialization for the central nervous system disorder treatment revealed the economic facts and figures that ended on March 31, 2014. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) net profit margin is -59.90% and weekly performance is -29.91%. On last trading day company shares ended up $10.17. Analysts mean target price for the company is $24.33. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) distance from 50-day simple moving average (SMA50) is -33.37%.
Aegerion Pharmaceuticals (NASDAQ:AEGR) was downgraded by investment analysts at Cowen and Company from an “outperform” rating to a “market perform” rating in a note issued to investors on Wednesday, TheFlyOnTheWall.com reports. They currently have a $36.00 target price on the stock, down from their previous target price of $85.00. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) shares fell -1.12% in last trading session and ended the day on $32.62. AEGR gross Margin is 89.70% and its return on assets is -45.10%.Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) quarterly performance is -47.53%.
Depomed Inc. (NASDAQ:DEPO) updated its FY14 earnings guidance on Thursday. The company provided EPS guidance of $0.00-$0.16 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.26, Analyst Ratings.Net reports. The company issued revenue guidance of $200-$215 million, compared to the consensus revenue estimate of $208.61 million. Depomed Inc. (NASDAQ:DEPO) shares moved down -15.64% in last trading session and was closed at $10.57, while trading in range of $10.29 – $12.10. Depomed Inc. (NASDAQ:DEPO) year to date (YTD) performance is -0.09%.
Shares of Dendreon Corp. (NASDAQ:DNDN) are down still reeling after the biotechnology company reported 2014 first quarter results yesterday that showed net product revenue for the quarter was $68.8 million compared to $67.6 million in the first quarter of 2013. Dendreon Corporation (NASDAQ:DNDN) ended the last trading day at $1.94. Company weekly volatility is calculated as 10.88% and price to cash ratio as 1.73.Dendreon Corporation (NASDAQ:DNDN) showed a negative weekly performance of -22.40%.